Health & Life Sciences

NEW YORK; July 20, 2017 – In a move to provide organizations with more comprehensive scientific informatics capabilities, Accenture (NYSE: ACN) has completed its acquisition of LabAnswer, a leading U.S.-based research and laboratory informatics technology consulting firm. 

NEW YORK; June 26, 2017 – Accenture (NYSE: ACN) has developed and introduced a new analytics platform to provide real-time insights on the status and performance of clinical trials for the life sciences industry. The platform, known as the Clinical Operations Insights Platform (COIP), is a module of the Accenture Life Sciences Cloud for R&D, an industry platform for running clinical trials that deliver better patient outcomes. 

NEW YORK; June 20, 2017 – Accenture (NYSE: ACN) has been positioned as a “Leader” in IDC Health Insights’ recently published report, “IDC MarketScape: Worldwide Life Sciences Drug Safety Services 2017 Vendor Assessment.” ¹ This is the second consecutive time Accenture has been named a Leader in the vendor assessment report, which is derived from qualitative and quantitative metrics as well as end-user feedback of drug safety service providers in the life sciences industry through the IDC MarketScape model. Click here for a link to the 2017 report. 

NEW YORK; June 8, 2017 –- Accenture today announced it will continue to serve as a catalyst for identifying and engaging with emerging innovators and disruptors with the second annual Accenture HealthTech Innovation Challenge. Building on the success of the inaugural program in which 500 startups participated, the Accenture HealthTech Innovation Challenge brings together leading-edge startups with prominent health and life sciences companies to tackle some of the world’s greatest health challenges including access, affordability and transparency. 

NEW YORK; June 1, 2017 – Accenture (NYSE: ACN) has agreed to acquire LabAnswer, a leading U.S.-based research and laboratory informatics technology consulting firm. Terms of the acquisition were not disclosed.

NEW YORK; Apr. 10, 2017 – Accenture (NYSE:ACN) today announced it will work with BioCelerate, a subsidiary of TransCelerate BioPharma Inc., a nonprofit focused on improving efficiencies in research and development, to develop a platform enabling its member companies to aggregate and analyze preclinical and clinical information to improve drug development efficiency and bring new medicines to patients faster. 

CHICAGO; Mar. 17, 2017 – Accenture (NYSE: ACN) has been named by Everest Group as the top leader in the 2017 PEAK Matrix Service Provider of the Year™ in healthcare and life sciences. The designation recognizes service providers who have demonstrated consistent leadership in the PEAK Matrix™ reports issued by Everest Group in the previous year. 

NEW YORK; Feb. 21, 2017 – Accenture (NYSE: ACN) has launched the Intelligent Patient Service Exchange, a digital marketplace of third-party technology solutions available to life sciences companies to enhance patient support and improve the overall patient treatment experience. 

CHICAGO; Feb. 9, 2017 – Accenture today announced the appointment of Laura Gurski as Senior Managing Director, Products – effective immediately. As the head of Accenture’s Customer and Channels Consulting Practice for Products, Ms. Gurski will oversee the development and delivery of marketing, customer service, commerce and sales transformation services. 

ARLINGTON, Va.; Feb. 8, 2017 – Accenture (NYSE: ACN) has entered into an agreement to acquire the U.S. federal government services business of Endgame Inc., a privately held endpoint detection and response (EDR) cybersecurity software company based in Arlington, VA. Endgame’s federal government services business, which will become part of Accenture Federal Services, specializes in proactive cyber defense, hunt-as-a-service capabilities, red teaming and cyber operations.